Bexson Biomedical is a biopharmaceutical company focused on delivering small molecules subcutaneously with our SeValent technology, to enable home health delivery. We are initially focused on addressing the opioid crisis by developing our BB106 non-opioid therapy for acute pain management. Our experienced team has a strong background in health innovation, clinical development and IP creation. Expertise in Pharma with Over 20 FDA Approvals and Leaders in Med-Tech Device Development with more than 130 US Patents. Bexson’s lead therapy, BB106, is a low-dose ketamine treatment for post-operative pain management, a$36B global market and leading driver of opioid addiction. Additionally, management believes its BB106formulation technology can be utilized to address various mental health indications.